In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best stocks to buy for financial stability. Investing in stocks is one of the most effective ...

Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion or more. Leverage the power of TipRanks' Smart Score, a data-driven ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other dividend stocks. During a time of great excitement about AI-driven capital gains ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best medical device stocks to buy right now. According to a report by Mordor Intelligence ...

Guggenheim analyst Vamil Divan maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of ...

J&J is exploring the sale of Cerenovus, a stroke care business, in a deal potentially worth $1 billion to $1.5 billion. The company spent over $30 billion on medtech acquisitions in the past three ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However ...

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Brooklyn Nets wing Cam Johnson is available for a deal, but it's possible he'll stay in town after Thursday's trade deadline. Ian Begley of SNY reported that news Tuesday. "The Nets' biggest trade ...

Johnson & Johnson (NYSE:JNJ) traded flat in the premarket on Wednesday after the pharma giant exceeded Street forecasts for Q4 2024, mainly due to its Innovative Medicine unit, while its MedTech ...